| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 05/31/2001 | WO2001038567A2 Genetic indicators of tobacco consumption |
| 05/31/2001 | WO2001038566A2 Screening method for candidate drugs |
| 05/31/2001 | WO2001038564A2 Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| 05/31/2001 | WO2001038503A2 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | WO2001038486A2 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001038331A2 Pyrazolo[1,5-d][1,2,4]triazines for enhancing cognition |
| 05/31/2001 | WO2001038330A1 Anhydrous mirtazapine crystals and process for the production thereof |
| 05/31/2001 | WO2001038329A1 Anhydrous mirtazapine crystals and process for producing the same |
| 05/31/2001 | WO2001038326A2 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | WO2001038325A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | WO2001038324A2 Imidazole derivatives and their use as raf kinase inhibitors |
| 05/31/2001 | WO2001038320A1 Vitamin d analogues |
| 05/31/2001 | WO2001038316A2 Sulfonyl oxazole amines and their use as 5-ht6 receptor ligands |
| 05/31/2001 | WO2001038315A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/31/2001 | WO2001038314A1 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
| 05/31/2001 | WO2001038312A1 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS |
| 05/31/2001 | WO2001038311A2 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | WO2001038310A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | WO2001038305A2 Novel il-8 receptor antagonists |
| 05/31/2001 | WO2001038304A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | WO2001038295A1 Sphingosine derivatives |
| 05/31/2001 | WO2001038293A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | WO2001037870A1 Treatment of autoimmune diseases by an agonistic cd40-binding protein |
| 05/31/2001 | WO2001037868A1 Assays and therapies for latent viral infection |
| 05/31/2001 | WO2001037857A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | WO2001037856A1 Urotensin-ii cyclic analogs |
| 05/31/2001 | WO2001037848A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | WO2001037840A1 Methods for treating mild cognitive impairment |
| 05/31/2001 | WO2001037839A1 Pernasal preparation |
| 05/31/2001 | WO2001037836A1 Diimino-piperazine derivatives for use as modulators of cell regulation |
| 05/31/2001 | WO2001037835A1 Novel compounds |
| 05/31/2001 | WO2001037832A2 Combination of riluzole and gabapentin and use thereof as medicine |
| 05/31/2001 | WO2001037830A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | WO2001037823A1 Substituted nitrobenzene derivatives as medicines and other useful uses thereof |
| 05/31/2001 | WO2001037819A2 Use of indirubine derivatives for making medicines |
| 05/31/2001 | WO2001037816A2 Coating of tablet cores |
| 05/31/2001 | WO2001037813A2 Multilayer preparation for a controlled, pulsed release of active substances |
| 05/31/2001 | WO2001037808A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | WO2001037801A1 Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| 05/31/2001 | WO2001037785A2 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | WO2001037780A2 Urotensin-ii analogs |
| 05/31/2001 | WO2000072880A3 Prevention and treatment of amyloidogenic disease |
| 05/31/2001 | WO2000071140A3 Methods and compositions for modulating immune response and for the treatment of inflammatory disease |
| 05/31/2001 | WO2000069472A3 Enzyme-activated anti-tumor prodrug compounds |
| 05/31/2001 | WO2000061754A3 Human proteins and polynucleotides encoding them |
| 05/31/2001 | WO2000056350A3 Methods of use of beta 1-integrin inhibitors |
| 05/31/2001 | WO2000047194A9 METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| 05/31/2001 | WO2000009512A3 Bipyridine manganese complexes |
| 05/31/2001 | WO1999064041A9 Multibinding agents that modulate nmda receptors |
| 05/31/2001 | WO1999024394A9 Compounds for the antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| 05/31/2001 | US20010002406 Administering an anesthetic to the area where capsaicin or an analogue are administered transdermally for neuropathic pain; kits containing two patches; desensitization of C fibers; peripheral neuropathy |
| 05/31/2001 | US20010002259 Applying a transdermal delivery system containing analgesicbuprenorphine sufficient to maintain an adequate onto the skin of the patient and maintaining the relative release rate to provide a specific plasma concentration |
| 05/31/2001 | DE19957156A1 New amino and fluoro substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocine derivatives useful in treatment of e.g. arrythmias, spasms, ischaemia, pain and neurodegenerative disorders |
| 05/31/2001 | DE19956791A1 New 2-heterocyclyl-4-arylsulfonyl-5-amino-oxazole derivatives useful in treatment of central nervous system disorders and as pesticides |
| 05/31/2001 | DE10058310A1 2-(3,5-Bistrifluormethylphenyl)-N-methyl-N-(6- morpholin-4-yl-4-o-tolylpyridin -3-yl ) isobutyramid 2- (3,5-Bis-trifluoromethyl) -N-methyl-N- (6-morpholin-4-yl-4-o-tolylpyridine -3-yl) -isobutyramide |
| 05/31/2001 | CA2706113A1 Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| 05/31/2001 | CA2395564A1 Novel compounds |
| 05/31/2001 | CA2395049A1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 05/31/2001 | CA2394803A1 Novel human protein kinases and protein kinase-like enzymes |
| 05/31/2001 | CA2392456A1 Assays and therapies for latent viral infection |
| 05/31/2001 | CA2392366A1 Major intrinsic protein (mip)-like polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2392365A1 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 05/31/2001 | CA2392362A1 Novel methods and compositions involving opioids and antagonists thereof |
| 05/31/2001 | CA2392327A1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 05/31/2001 | CA2392225A1 Novel il-8 receptor antagonists |
| 05/31/2001 | CA2392149A1 2-arylquinoline derivatives, preparation and therapeutic use thereof |
| 05/31/2001 | CA2391962A1 Multilayer preparation for a controlled, pulsed release of active substances |
| 05/31/2001 | CA2391575A1 Heterocyclic ketone and thioester compounds and uses |
| 05/31/2001 | CA2391288A1 Ethers of o-desmethyl venlafaxine |
| 05/31/2001 | CA2391103A1 Pyrazolo¬1,5-d|¬1,2,4|triazines for enhancing cognition |
| 05/31/2001 | CA2390923A1 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity |
| 05/31/2001 | CA2390772A1 Genetic indicators of tobacco consumption |
| 05/31/2001 | CA2390465A1 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 05/31/2001 | CA2389869A1 Preparation for nasal administration |
| 05/31/2001 | CA2389679A1 Novel sulfonyloxazolamines |
| 05/31/2001 | CA2389537A1 Mixture of pomegranate seed oil and juice products |
| 05/31/2001 | CA2387591A1 Use of indirubine derivatives for making medicines |
| 05/31/2001 | CA2387575A1 Coating |
| 05/31/2001 | CA2386955A1 Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes |
| 05/30/2001 | EP1103553A2 Substituted heterocyclic derivatives |
| 05/30/2001 | EP1103546A1 Process for preparation of pyridine derivatives |
| 05/30/2001 | EP1103545A1 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide |
| 05/30/2001 | EP1103257A2 Method for treating migraine symptoms using acetominophen |
| 05/30/2001 | EP1103256A1 Use of ketamine for the treatment of neuroendocrine immune dysfunction und algogenic psychosyndrome |
| 05/30/2001 | EP1103243A2 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance p |
| 05/30/2001 | EP1102862A1 Antisense oligonucleotides targeted to il-15 |
| 05/30/2001 | EP1102776A1 Water soluble prodrugs of hindered alcohols or phenols |
| 05/30/2001 | EP1102769A2 Tricyclic carboxamides |
| 05/30/2001 | EP1102762A2 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists |
| 05/30/2001 | EP1102761A2 Cyclopentabenzofuran derivatives and their use |
| 05/30/2001 | EP1102758A1 Particle-forming compositions containing fused pyrrolocarbazoles |
| 05/30/2001 | EP1102756A1 Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| 05/30/2001 | EP1102755A1 Substituted isoxazole derivatives as estrogen receptor modulators |
| 05/30/2001 | EP1102754A1 Imidazoles and related compounds as alpha-1a agonists |
| 05/30/2001 | EP1102753A2 Pyrazoles as estrogen receptor modulators |
| 05/30/2001 | EP1102752A1 Succinoylamino lactams as inhibitors of a beta protein production |
| 05/30/2001 | EP1102751A1 Novel bi- and tri-cyclic aza compounds and their uses |
| 05/30/2001 | EP1102748A1 New 4-amino-1-aryl-pyridine-2-ones with anticonvulsive action and method for producing same |
| 05/30/2001 | EP1102597A1 Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5ht 4 receptors |
| 05/30/2001 | EP1102589A1 Topical compositions comprising an opioid analgesic and an nmda antagonist |